MindRank Re-Listed as Hangzhou's 'Near-Unicorn' Enterprise and Files IPO Prospectus
MindRank
AI Drug Developer
On April 23, 2026, the "10th Everything Growth Conference," hosted by the Zhejiang Provincial Committee of the China Democratic建国Party, the Zhejiang Provincial Federation of Industry and Commerce, and the China Investment Development Promotion Association, was held in Hangzhou. During the conference, the Hangzhou Entrepreneurship Investment Association, Welian, and Hangzhou Bank jointly released"2026 Hangzhou Unicorn and Quasi-Unicorn Enterprises List"
MindRank Ltd. has once again been honored with the title of "Hangzhou Pre-Unicorn Enterprise" for its outstanding technological innovation and development potential.Fully demonstrates the strength of the company as a benchmark enterprise in the intersection of life health and artificial intelligence in Hangzhou.
From 2018 to 2026, the number of unicorn companies in Hangzhou increased from 26 to 48, and the number of quasi-unicorn companies grew from 105 to 413, fully demonstrating the remarkable effectiveness of Hangzhou's "incubation-acceleration-industrialization" full-chain cultivation system.
MindRank's five consecutive years on the list aligns closely with Hangzhou's implementation of the "AI+" initiative, supporting innovation in cutting-edge fields and developing new quality productive forces. Empowered by policies, capital, and technology,MindRank will continue to deepen its focus on the "AI + pharmaceuticals" track, using disruptive technologies to tackle difficult drug targets, bringing better therapies to patients worldwide, and injecting strong momentum into the high-quality development of the biopharmaceutical industry in Hangzhou and even China.
Click to View the Official Release of the Rankings
About MindRank
MindRank is a globally leading AI for drug discovery technology innovation company dedicated to empowering new drug research and development through machine learning, reinforcement learning, and first-principles calculations. Relying on its self-developed one-stop AI platform that deeply integrates biology, structural biology, chemistry, and medicine, it expands the boundaries of pharmaceutical technology, enabling more diseases to be treatable and helping more lives regain health.
END
For more information, please visit the website:
www.mindrank.ai
Contact: bd@mindrank.ai pr@mindrank.ai
Other: info@mindrank.ai